SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending downwards due to a recently announced $1.5 billion stock offering, which investors fear will dilute the stock's value; the offering's purpose is to enhance the company's capital position and fund future growth. While some investors view this as a buying opportunity and trust in management's vision, others are concerned about the timing and lack of clear communication regarding the use of proceeds, especially with a potential S&P 500 inclusion decision looming.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending due to increased volume and speculation of a potential short squeeze, reminiscent of other recent high-flying stocks. The community highlights the low float and increasing number of watchers as potential catalysts for a significant price increase. Some users are also discussing recent clinical trial data and company financials, contributing to the heightened interest.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to a potential short squeeze, with the stock price experiencing a significant surge and prompting community discussions about its low float and possible further gains. Some traders are comparing it to previous high-flying stocks and pointing to the potential for a continued run, while others caution about a possible correction. Overall, excitement and speculation are high as the stock captures the attention of traders looking for quick profits.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies (QCLS) is trending due to news that investor Martin Shkreli has taken a major stake, fueling discussions of a potential short squeeze and comparisons to $SMX's recent surge.  The community is focused on Shkreli's bold price target and the company's potential in photonics versus quantum computing, with bullish investors anticipating further gains.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending due to community excitement around its low float and comparisons to similar Hong Kong-based stocks that have experienced rapid gains; traders are speculating about a potential short squeeze. Discussions highlight the company's expansion into the EV and AI sectors, with some drawing parallels to the setup of other high-flying tickers. The stock's potential is amplified by its strategic position in Hong Kong's growing infrastructure and security needs.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors debate the implications of a recent $1.5 billion stock offering, with some viewing it as a strategic move for future growth and others expressing concerns about dilution and the company's current valuation. Community discussions revolve around whether the offering signals positive developments or exposes fundamental weaknesses, especially given Oklo's pre-revenue status in the nuclear energy sector. Broader market interest in nuclear energy, spurred by AI's increasing power demands, adds another layer to the conversation around Oklo's potential.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik shares are surging as investors cheer the company's first non-GAAP profit and strong revenue growth, signaling a potential inflection point. The community is encouraged by raised guidance and Rubrik's positioning in cybersecurity, data protection, and AI. Some are pointing to the large short interest as a possible catalyst for even higher prices.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending due to a mixed reaction to earnings and the CFO's departure, with community members debating whether the dip presents a buying opportunity or reflects deeper issues. Despite beating EPS and revenue estimates and achieving positive cash flow, some investors are concerned about lowered guidance and competition in the cybersecurity space, while others see the stock as undervalued relative to peers like Crowdstrike. Discussions also include speculation about a potential company sale or acquisition.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending amid discussions about its competitive positioning in the face of emerging AI technologies like OpenAI's DocuGPT, leading to both bullish and bearish sentiments. While some investors view the dip as a buying opportunity due to the company's strong fundamentals and potential AI integrations, others are concerned about commoditization and potential disruption to DocuSign's core business. Community members are actively debating DocuSign's long-term strategy and ability to maintain market share in the evolving landscape.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara Inc. ($IOT) is trending as investors assess its growth prospects amid mixed analyst ratings and price target adjustments. Community discussion revolves around its high valuation, potential for dilution, and reliance on mega-deals, even after reporting its first GAAP profitable quarter. Despite some concerns, there's optimism surrounding the company's potential in the IoT sector, particularly with AI-driven solutions and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The stock was bought...

Cassava Sciences Sees Unusually High Options Volume (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 8,896 call options on the company. This represents an...

Insider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 73,385 Shares of Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction on Wednesday, November 19th. The stock was bought at an average...

Cassava Sciences (NASDAQ:SAVA) Trading Down 3% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Shares Down 3% - Time to Sell...

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you...

Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with mild to moderate Alzheimer’s disease in its second Phase 3 study.The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said.Cassava added that it would discontinue the Alzheimer’s disease development program with Simufilam by the end of the second quarter of 2025. &nbsp;REFOCUS-ALZ was discontinued on Nov. 25 last year after the company identified that a previous phase 3 study failed to yield positive results.Cassava CEO Rick Barry acknowledged the results were "unambiguous" and added that the company was “disappointed.”“Cassava will discontinue all efforts to develop Simufilam for Alzheimer’s disease, and we expect to phase out the program by the end of Q2 2025,” he said.The CEO added that the company has initiated preclinical studies to gauge the potential of Simufilam in treating TSC-related epilepsy.Company CFO Eric Schoen said the firm continues to be committed to enhancing shareholder value. “Cassava is well-capitalized with approximately $128.6 million in cash and cash equivalents as of Dec. 31, 2024,” he added.Cassava reported a net loss of $27.60 million in the three months ended December 2024 compared to a net loss of $20.92 million in the corresponding quarter of 2023.On Stocktwits, retail sentiment about Cassava Sciences climbed further into the ‘bullish’ territory (60/100), while message volume jumped from ‘normal’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:650/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_25_at_1_50_58_PM_png_d88af5aac9.webp" alt="SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits" width="650" height="146"><figcaption>SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects the share price to drop further in the coming days.<stembedurl>https://stocktwits.com/pg3015/message/609181500</stembedurl>Another user expressed optimism, highlighting the company’s debt-free status.<stembedurl>https://stocktwits.com/mcrotary/message/609180826</stembedurl>SAVA stock has lost over 30% this year and is down by over 90% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/merck-enters-license-agreement-with-china-based-hengrui-pharma/ch7yxJsRbdw">Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025. 

Equity

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc...

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA Cassava Sciences, Inc. Securities Fraud Class...

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm Lead Plaintiff Deadline on February 10, 2025...

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAVA News

SAVACassava Sciences Inc